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Background: Post-translational modification of histone tails by methylation plays an important role in tumorigenesis.
In this study, we investigated the nuclear expression of H3K4me3, H3K9me3 and H4K20me3 in early-stage colon cancer
in relation to clinical outcome.
Methods: Tumor tissue cores of 254 TNM stage I-III colorectal cancer patients were immunohistochemically stained for
H3K4me3, H3K9me3 and H4K20me3 and scored using the semi-automated Ariol system. Cox proportional hazard trend
analyses were performed to assess the prognostic value of the combined markers with respect to patient survival and
tumor recurrence.
Results: The histone methylation markers only showed prognostic value in early-stage (TNM stage I and II) colon
cancer. Therefore, only this patient set (n = 121) was used for further statistical analyses. Low nuclear expression of
H3K4me3, and high expression of H3K9me3 and H4K20me3 were associated with good prognosis. In combined marker
analyses, the patient group showing most favorable expression (low H3K4me3, high H3K9me3 and high H4K20me3)
was associated with the best prognosis. Multivariate trend analyses showed significantly increased hazard ratios (HR) for
each additional marker showing unfavorable expression, as compared to the “all favorable” reference group. The HR for
disease-free survival was 3.81 (1.72-8.45; p = 0.001), for locoregional recurrence-free survival 2.86 (1.59-5.13; p < 0.001)
and for distant recurrence-free survival 2.94 (1.66-5.22; p < 0.001).
Conclusions: Combined nuclear expression of histone modifications H3K4me3, H3K9me3 and H4K20me3 is prognostic
in early-stage colon cancer. The combination of expression of the three histone modifications provides better stratification
of patient groups as compared to the individual markers and provides a good risk assessment for each patient group.
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In tumor cells, numerous changes in epigenetic regulation
of gene expression have been reported [1]. As epigenetic
mechanisms are potentially reversible, they represent suit-
able targets for the development of new anti-cancer ther-
apies. Both DNA methylation and histone modifications
might therefore present as possible new biomarkers in can-
cer. In this study, we investigated the clinical prognostic* Correspondence: p.j.k.kuppen@lumc.nl
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unless otherwise stated.value of several histone modifications in early-stage (TNM
stage I and II) colon cancer.
Epigenetic regulation of gene expression through post-
translational modification of histone proteins by methyla-
tion plays an important role in many biological processes,
including cell-cycle regulation, DNA damage- and stress
response, embryonic development and cellular differenti-
ation [2]. The most extensively studied histone methyla-
tion sites include histone H3 lysine 4 (H3K4), H3K9 and
H4K20. Altered expression of these - and other - histone
modifications has been reported in cancer [3]. For ex-
ample, expression of H3K4me3 was shown to have prog-
nostic value in hepatocellular carcinoma [4] and renal cellLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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was prognostic in acute myeloid leukemia [6], salivary
carcinoma [7] and bladder cancer [8]. Expression of
H4K20me3 was shown to be correlated to tumor progres-
sion and prognosis in non-small cell lung cancer [9].
Marión et al. showed that loss of H4K20me3 contributed
to telomere reprogramming and hence a higher tumori-
genic potential [10]. As these three histone methylation
markers have been found to contribute to the tumorigenic
process in various cancers, we hypothesized that these his-
tone modifications would correlate to clinical outcome in
colon cancer.
In addition to the individual functions of the histone
modifications, they work together regulating gene ex-
pression and chromatin structure in different regions of
the genome. H3K4me3 and H3K9me3 both regulate
gene promoter activity and are mutually exclusive at
promoter regions [11]. H4K20me3 and H3K9me3 are
both present on pericentric regions [12,13] and are crit-
ical for condensation of chromatin at these regions. Both
H3K9me3 and H4K20me3 have also been found to be
enriched on imprinted genes [14]. The study by McEwen
et al. also showed that all three histone methylation
marks H3K4me3, H3K9me3 and H4K20me3 form a tri-
mark signature on imprinting control regions [14]. Based
on the overlapping functions of the three histone methy-
lation marks, we hypothesized that combining these
three modifications in survival analyses would be more
informative than the individual markers with respect
to patient survival and tumor recurrence. A combin-
ation of high expression of activating histone modification
H3K4me3 and low expression of silencing modifications
H3K9me3 and H4K20me3 was expected to correlate with
poor clinical outcome in colon cancer. Using immunohis-
tochemistry and semi-automated scoring, nuclear expres-
sion of H3K4me3, H3K9me3 and H4K20me3 was
determined on a tissue microarray of colorectal cancer pa-
tients, and subsequently correlated to clinical outcome.
Methods
Patient selection
Tumor tissues were collected from a consecutive series
of 409 colorectal cancer patients who underwent surgi-
cal resection of a primary colorectal tumor at the Leiden
University Medical Center (LUMC) between 1991 and
2001. Patients were excluded from the study analyses
when patients had a history of cancer other than basal
cell carcinoma or in situ tumors, had multifocal tumors
or received preoperative treatment. Data were right-
censored when patients were alive or free of recurrence
at their last follow-up date. Patient records information
was anonymized and de-identified prior to analysis ac-
cording to national ethical guidelines (“Code for Proper
Secondary Use of Human Tissue”, Dutch Federation ofMedical Scientific Societies), and approved by the Med-
ical Ethical Committee of the Leiden University Medical
Center (LUMC). In the study cohort, we only included
patients with TNM stage I-III tumors (n = 259). Of 254
patients, complete data on all the studied markers were
available. This study was performed according to the
REMARK guidelines (NCI-EORTC) [15].
Tissue microarray construction and
immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tumor tissues
from 409 colorectal cancer patients were collected from
the LUMC pathology archives and used to construct a
tissue microarray (TMA), as described previously [16].
Three tumor tissue cores, and if available one normal
tissue core, were included in the TMA for each patient.
Sections of 4 μm were cut from each TMA block and
used for immunohistochemical (IHC) staining. Histolog-
ically normal colon tissues, as determined by an experi-
enced pathologist, from 29 patients were also included
and IHC stained. The following antibodies were used for
IHC: anti-H3K4me3 (ab8580, ABcam, Cambridge, UK),
anti-H3K9me3 (07-442, Millipore, Billerica, MA, USA)
and anti-H4K20me3 (ab9053, Abcam). All primary anti-
bodies were used at predetermined optimal dilutions
and IHC was performed using a standard IHC protocol
[17]. Briefly, endogenous peroxidase was blocked by in-
cubating the sections in a 0.3% solution of hydrogen
peroxide (in PBS) for 20 min. Antigen retrieval was per-
formed by heating the sections for 10 min at 95°C in a
citrate buffer (pH 6; pH Low Target Retrieval Solution,
Dako, Glostrup, Denmark), followed by overnight (16 hrs)
incubation of the respective primary antibodies. Staining
was visualized using the Dako REAL™ EnVision™ Detec-
tion System, Peroxidase/DAB+, Rabbit (Dako). The
stained TMA slides were scanned using a 20x magnifica-
tion on the Ariol system (Leica Microsystems, Wetzlar,
Germany), followed by marking the tumor cell areas or
normal colon epithelium for each tissue punch upon vis-
ual inspection on the computer screen. The Ariol system
is specifically designed to recognize cells, nuclei, cell
membranes and pixel intensity. For each type of staining
(membranous, cytoplasmatic or nuclear), different soft-
ware packages are available. In the nuclear staining pack-
age, the system can be trained to recognize nuclei with a
minimum pixel intensity that corresponds to positive
staining. By carefully fine-tuning of the shape and intensity
settings for each individual immunohistochemical stain-
ing, we verified that the system only counted positively
stained nuclei. For each TMA section, several random
cores were evaluated by visual inspection after automatic
analysis in order to verify that the system correctly identi-
fied positively stained nuclei. Automatic analysis of the per-
centage of positively stained nuclei (nuclear expression)
Table 1 Patient characteristics of the study cohort
Study cohort Colon stage I + II
(n = 254) (n = 121)
N (%) n (%)
Age at randomization
<50 32 12.6 11 9.1
50-75 161 63.4 80 66.1
>75 61 24 30 24.8
Gender
Male 128 50.4 61 50.4
Female 126 49.6 60 49.6
TNM stage
I 53 20.9 30 24.8
II 113 44.5 91 75.2
III 88 34.6
Tumor location




Standard error 2.32 0.21
MSS status
MSS 175 68.9 20 16.5
MSI 34 13.4 75 62
Unknown 45 17.7 26 21.5
Tumor in follow up
No 215 84.6 105 86.8
Yes 39 15.4 16 13.2
Adjuvant therapy
No 206 81.1 117 96.7
Yes 48 18.9 4 3.3
Patient characteristics are shown for both the study cohort (n = 254) and the
patients with TNM stage I and II colon cancer as used for the statistical analyses
(n = 121). Patient selection was based on availability of FFPE tissues, available
data for all three markers, and information about the listed covariables. The study
cohort selection was representative for the entire colorectal cancer series.
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sue core.
Statistical analyses
Data were analyzed in consultation with a statistician
(H.P.) using SPSS 20.0 for Windows (SPSS Inc, Chicago,
USA). The mean percentage of positive nuclei of the
three tumor cores was calculated for each individual
patient and this percentage was used for all statistical
analyses. Normality of the data was tested using the
Shapiro-Wilk test. Non-parametric Wilcoxon signed-
rank tests were performed to assess the differences in
mean nuclear expression between the paired tumor and
normal tissues (n = 29) for each of the individual
markers. The Cox proportional hazard model was used
for univariate and multivariate survival analyses of indi-
vidual and combined markers. Covariates included in all
multivariate analyses were age at operation, gender,
TNM tumor stage (tumor stages I-III), tumor location,
tumor size, microsatellite stability (MSS) status. Add-
itionally, covariates tumor in the follow up and adjuvant
therapy were entered as time-dependent covariates. Pa-
tients in the study cohort (TNM stage I and II colon pa-
tients only) were divided into high and low expression
groups based on the median expression of each of the
markers separately. Based on the cellular function of
each of the histone modifications, we expected low
H3K4me3, high H3K9me3 and high H4K20me3 to be
associated with a better prognosis (“all favorable”). For
combinatorial analyses, patients were divided into
groups based on the number of favorable markers (all fa-
vorable, 1 favorable, 2 favorable and all unfavorable).
Univariate and multivariate trend analyses were per-
formed using the group numbers as continuous variables
to assess the influence of the combined markers on pa-
tient survival and tumor recurrence. Resulting hazard ra-
tios (HR) represent the HR for each unit of increase
(increase in group number, and hence an increase in the
number of markers showing unfavorable expression).
Overall survival (OS) was defined as the time from sur-
gery until death (by any cause). Disease-specific survival
(DSS) was defined as the time from surgery until death
by colorectal cancer. Loco-regional recurrence-free sur-
vival (LRRFS) was defined as the time from surgery until
the occurrence of a (loco)regional recurrence or death
by cancer. Distant recurrence-free survival (DRFS) was
defined as the time from surgery until the occurrence of
a distant recurrence or death by cancer. Cumulative in-
cidence curves were made for DSS, LRRFS and DRFS,
accounting for competing risks [18]. Kaplan-Meier
curves (for OS) or cumulative incidence curves (for DSS,
LRRFS and DRFS) were used to visualize differences be-
tween the three patient groups for OS. For all statistical
analyses, two-sided p-values ≤ 0.05 were considered asstatistically significant, and p-values 0.05 < p ≤ 0.1 were
considered a trend.
Results
Patient selection for statistical analyses
In this study, we analyzed 254 patients with TNM stage
I-III colorectal cancer, with no prior history of cancer or
preoperative treatment and of whom complete clinico-
pathological data were available (Table 1). Combined
marker analyses, based on the number of favorable
markers, showed statistically significant discrimination
between patient groups in early-stage (TNM stage I and
II) colon cancer (n = 121). Multivariate trend analyses
showed significant differences between the patient groups
for patients with TNM stage I or II colon cancer (p =
Benard et al. BMC Cancer 2014, 14:531 Page 4 of 9
http://www.biomedcentral.com/1471-2407/14/5310.005), but no significant differences for patients with
TNM stage I or II rectal cancer (p = 0.256). For patients
with TNM stage III, no significant differences were ob-
served for patients with either colon (p = 0.7) or rectal
cancer (p = 0.6). Together, these results indicate prognos-
tic value of H3K4me3, H3K9me3 or H4K20me3 expres-
sion in early-stage colon cancer patients. Therefore,
patients with TNM stage III colorectal cancer or TNM
stage I and II rectum cancer were excluded from further
analyses. The resulting patient cohort consisted of 121 pa-
tients with TNM stage I or II colon cancer, with a mean
follow-up of 9.4 years.
Nuclear expression in tumor versus normal tissues
Comparison of expression between paired tumor and nor-
mal tissues was preceded by testing normality of expres-
sion distribution data in the stage I and II colon cancer
tissues per histone modification using the Shapiro-Wilk
test. As the data of the individual markers were not nor-
mally distributed, we used the Wilcoxon signed-rank test
to compare the expression in the paired tumor and nor-
mal tissues (n = 29). Marker expression was defined as the
percentage of positively stained nuclei per tissue core.
Representative staining of tumor tissue cores is shown in
Figure 1. Statistically significant differences between tumor
and normal samples were observed for H3K9me3 (p =
0.001) and H4K20me3 (p = 0.01), but not for H3K4me3
(p = 0.9) (Figure 2A).
Survival analyses of individual markers
Median expression of each individual marker was used
to divide the patients into high and low expression
groups. The median expression for each of the individual
markers in tumor tissues was 12.1% for H3K4me3, 65.5%
for H3K9me3 and 65.4% for H4K20me3. Low expression




Figure 1 Correct identification of positively stained and negative
nuclei for each individual marker. The Ariol system trainer overlay
shows correct identification of positive (indicated by yellow dots) and
negative (blue dots) nuclei in tumor tissues. TMA slides were scanned
using a 20x magnification. Shown for all individual markers are positively
stained nuclei (top row) and negative tumor cores (bottom row).and lower chances of tumor recurrence (Figure 2B).
In contrast, high expression of both H3K9me3 and
H4K20me3 was associated with better patient survival
and lower chances of tumor recurrence in our study
cohort (Figure 2B). These findings are also reflected
in the 5-year survival rates (Table 2). Both univariate
and multivariate Cox regression analyses show signifi-
cant differences between the low and high expression
patient groups with respect to DSS, LRRFS and DRFS
(Table 2).
Survival analyses of combinations of two markers
We analyzed the prognostic value of combinations of
two of the histone methylation markers. As both
H3K4me3 and H3K9me3 are mostly found on gene pro-
moter regions, and H4K20me3 and H3K9me3 in consti-
tutive chromatin at pericentric regions, we hypothesized
that these combinations of two histone modifications
would result in better stratification of patients as com-
pared to the individual markers. Multivariate analyses
showed that combining the histone modifications indeed
resulted in better separation of the patient groups with
respect to patient survival and tumor recurrence. For
the combination of gene promoter-associated modifica-
tions H3K4me3 and H3K9me3, we observed that the pa-
tient group with the most unfavorable expression
pattern (high H3K4me3 and low H3K9me3) showed the
shortest disease-free survival (trend analysis HR 2.05;
p = 0.004) and distant recurrence-free survival (trend
analysis HR 1.96; p = 0.001) as compared to the other
patient groups. For the combination of pericentric region-
associated modifications H4K20me3 and H3K9me3, the
group with the most favorable expression (high expression
of both markers) showed significantly better disease-free
survival (HR 2.01; p = 0.005) and distant recurrence-free
survival (HR 1.77; p = 0.004) as compared to the other pa-
tient groups.
Survival analyses of H3K4me3, H3K9me3 and H4K20me3
combined
To further improve the stratification of patients, we per-
formed Cox regression survival analyses using the com-
bined expression patterns of all three markers H3K4me3,
H3K9me3 and H4K20me3. Low expression of activating
modification H3K4me3 and high expression of silencing
modifications H3K9me3 and H4K20me3 was expected to
be associated with good prognosis, and was therefore used
as the “all favorable” reference group. Patients were di-
vided into 4 groups, based on the number of markers
showing clinically favorable or unfavorable expression.
This resulted in the following grouping: all favorable
(group 1; H3K4me3 low and both H3K9me3 and
H4K20me3 high), one out of three unfavorable (group 2),











Figure 2 Nuclear expression of individual markers. (A). Displayed are differences in nuclear expression, measured as the percentage of
positively stained nuclei (y-axis), between normal and tumor tissues (n = 29). Boxplots show the median and range of expression of each of the
individual markers in normal (N) and tumor (T) samples (x-axis). P-values represent statistical differences between normal and tumor samples,
calculated using the Wilcoxon signed rank test. (B). Cumulative incidence curves, accounting for competing risks, showing the difference in
survival between high and low expression groups of each of the individual markers. 5-year survival rates are included as percentages (in gray);
p-values represent the statistical differences between the two patient groups in multivariate analyses. Numbers of patients in each group are
indicated in each figure (n).
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H4K20me3 low). Both univariate and multivariate trend
analyses showed that the more markers showed unfavor-
able expression, the shorter the patient survival (DSS) and
recurrence-free survival times (both LRRFS and DRFS)
(Figure 3A). The survival plots of OS, DSS, LRRFS and
DRFS are shown in Figure 3B. Hazard ratios for the indi-
vidual patient groups could not be calculated accurately,
as not enough events (either death or recurrence of the
tumor) occurred in the reference group (group 1;
Figure 3B). Therefore, using multivariate trend analyses,
we calculated hazard ratios for each additional marker
showing unfavorable expression, as compared to the “allfavorable” reference group. The calculated HRs were 1.46
(1.04-2.05; p = 0.03) for OS, for DSS 3.81 (1.72-8.45; p =
0.001) for DSS, 2.86 (1.59-5.13; p < 0.001) for LRRFS and
2.94 (1.66-5.22; p < 0.001) for DRFS. Combining all three
markers resulted in better stratification and separation of
the patient groups as compared to the single markers or
the combinations of only two of the studied markers.
Discussion
Aberrant gene expression is a common feature of cancer
cells, which is caused by a combination of gene mutations
and aberrant regulation of gene expression by epigenetic
mechanisms, including DNA methylation, microRNAs
Table 2 Survival analyses single markers in TNM stage I and II colon cancer patients
OS DSS LRRFS DRFS
H3K4me3
Univariate p-value 0.4 0.02 0.01 0.01
HR 1.26 4.45 3.54 3.63
(95% CI) (0.75-2.11) (1.29-15.38) (1.32-9.49) (1.36-9.73)
Multivariate p-value 0.3 0.04 0.01 0.01
HR 1.36 3.79 3.86 3.57
(95% CI) (0.79-2.33) (1.06-13.56) (1.38-10.77) (1.29-9.81)
5-year survival rates Low expression 73% 95% 93% 94%
High expression 76% 82% 74% 77%
H3K9me3
Univariate p-value 0.07 0.02 0.07 0.02
HR 0.61 0.30 0.47 0.36
(95% CI) (0.36-1.04) (0.12-0.86) (0.21-1.08) (0.16-0.85)
Multivariate p-value 0.2 0.01 0.05 0.01
HR 0.69 0.26 0.42 0.29
(95% CI) (0.39-1.24) (0.09-0.77) (0.17-1.01) (0.12-0.75)
5-year survival rates Low expression 64% 78% 71% 74%
High expression 86% 96% 92% 92%
H4K20me3
Univariate p-value 0.1 0.01 0.02 0.04
HR 0.67 0.24 0.34 0.41
(95% CI) (0.40-1.12) (0.08-0.72) (0.14-0.81) (0.18-0.95)
Multivariate p-value 0.02 0.02 0.008 0.01
HR 0.51 0.21 0.29 0.31
(95% CI) (0.29-0.89) (0.06-0.67) (0.12-0.72) (0.13-0.77)
5-year survival rates Low expression 67% 80% 74% 77%
High expression 80% 94% 90% 91%
Shown are the results of the univariate and multivariate analyses of all individual markers in TNM stage I and II colon cancer patients, with all p-values and hazard
ratios (HR) with their 95% confidence intervals (95% CI). OS = overall survival, DSS = disease-specific survival, LRRFS = locoregional recurrence free survival, DRFS =
distant recurrence free survival. The low expression group (below-median expression) was used as reference group. 5-year survival rates are given for both low
and high expression groups. Statistically significant differences (defined as p < 0.05) are shown in bold, trends (p < 0.1) in Italic.
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crucial role in many cellular processes during embryonic
development, cell proliferation and cellular differentiation
[2]. In cancer, aberrant expression of histone modifica-
tions has been described frequently [1]. Therefore, we in-
vestigated the nuclear expression of three well-studied
histone modifications in colon cancer.
In this study, we found that nuclear expression of his-
tone trimethylation on H3K4, H3K9 and H4K20 has
prognostic value in early-stage colon cancer. Changes in
expression of key histone modifications are found in
early-stage tumors, which would be expected because
tumor cells require instant changes in gene expression
and chromatin structure in order to promote cell pro-
liferation and tumor cell survival. Several epigenetic
factors have been shown to be altered in early-stage
cancer, including histone-modifying enzymes and histonemodifications [19,20], DNA methylation [21,22] and
microRNAs [23]. We only observed differences between
the patient groups in colon tumors, whereas in rectum tu-
mors no difference was observed. The observed differ-
ences between the colon and rectum tumors with respect
to the studied histone modifications may be due to differ-
ences in biology of the tissues of origin. Several other
studies have suggested that rectum and colon tumors
show differential gene expression signatures [24,25]. This
could be due to changes in epigenetic regulatory mecha-
nisms. Detection of aberrant expression of prognostic his-
tone modifications, such as described in this study in
early-stage colon cancer, could facilitate the risk assess-
ment and subsequent decisions for treatment for specific
patient groups at early stages of the disease.
The results of the survival analyses of the individual
markers reflect our expected results based on the cellular
Figure 3 (See legend on next page.)
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Figure 3 Univariate and multivariate trend analyses of all markers combined. (A). Results of the univariate and multivariate trend analyses
of combined markers H3K4me3, H3K9me3, and H4K20me3. HR represents the hazard ratio for each unit of increase, thus each additional marker
showing unfavorable expression. 95% CI: 95% confidence interval for each HR. OS: overall survival; DSS: disease-specific survival; LRRFS: locoregional
recurrence-free survival; DRFS: distant recurrence-free survival. (B). Kaplan-Meier curves are shown for OS, including the number of patients in each
patient group (n), based on the number of markers showing unfavorable expression. Patients were divided into the following groups: all favorable
(group 1; H3K4me3 low and both H3K9me3 and H4K20me3 high), one out of three unfavorable (group 2), two out of three unfavorable (group 3), and
all unfavorable (group 4; H3K4me3 high and both H3K9me3 and H4K20me3 low). Cumulative incidence curves, accounting for competing risks, are
shown for DSS, LRRFS and DRFS. Multivariate p-values have been included in each of the combined marker graphs.
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methylation of H3K4 is a modification found on gene pro-
moter regions and is associated with activation of gene
transcription [26], and higher expression of H3K4me3 in
tumors could lead to aberrant gene transcription, includ-
ing genes required for cell survival, proliferation and
migration. In literature, poor prognosis was indeed re-
ported for patients with tumors showing high expression
of H3K4me3 [4]. Histone modification H4K20me3 is a
known repressive mark [13], and key modification regulat-
ing compaction of the chromatin in pericentric regions,
which makes it crucial for proper chromosome segrega-
tion during cell division and for maintenance of genome
integrity [12]. Consequently, loss of H4K20me3 was ex-
pected to be associated with a worse prognosis for the pa-
tient, which has indeed been shown in literature [9].
Finally, for H3K9me3, literature shows conflicting results
with respect to patient survival and prognosis [6-8,27],
depending on the type of cancer. Histone modification
H3K9me3 is associated with silencing of gene transcrip-
tion [26], and can hence be involved in aberrant silen-
cing of tumor suppressor genes (i.e. DCC [28]). On the
other hand, H3K9me3 prevents aberrant expression of
(onco)genes and represses the abundant repetitive se-
quences in the genome [29-31]. On the basis of the func-
tion of H3K9me3 as a silencing modification, we expected
H3K9me3 expression to be comparable to H4K20me3
expression with respect to clinical outcome. Our results
confirmed the hypotheses based on these individual func-
tions, as high expression of H3K4me3 and low expression
of H3K9me3 and H4K20me3 are correlated with shorter
patient survival and higher chances of tumor recurrence.
Combined marker analyses showed that favorable ex-
pression of all markers (low H3K4me3, high H3K9me3
and high H4K20me3, as based on the individual marker
analyses) was associated with the best prognosis with re-
spect to patient survival and tumor recurrence. With
each additional marker showing more unfavorable ex-
pression, the HR increased significantly about 3-fold for
DSS, LRRFS and DRFS, indicating that combining all
three methylation marks resulted in better separation of
the patient groups as compared to individual markers.
Combining multiple markers in survival analyses canthus be beneficial in identifying high-risk patient groups
and to determine treatment strategies accordingly. To
our knowledge, this is the first study to combine these
three markers in survival analyses. In literature, multiple
histone modifications have been studied in cancer tissues
but have never been combined in survival analyses
[8,32-35]. In addition, expression of histone modifications
was not always correlated to clinical outcome [36], or
were found to have no prognostic value in cancer [37].
Conclusions
In conclusion, in this study we have shown that com-
bined nuclear expression of histone trimethylation on
H3K4, H3K9 and H4K20 is prognostic in early-stage
colon cancer and that combined expression of the three
histone modifications provides better stratification of pa-
tient groups and therefore provides a better risk assess-
ment as compared to the individual markers. The
clinically prognostic value of the histone modifications
presented in this study underlines the consequences of
epigenetic dysregulation in tumorigenesis.
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